{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028684","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.028666+00:00","generated_at":"2026-06-11T09:55:04.283684+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Elite Pharma Q1 revenue up 17% to $9.0M; net income up 267% to $1.1M","bullets":["Revenue $9.0M (+16.9% YoY); operating profit $1.6M (+60% YoY).","Net income attributable to common shareholders $1.1M (+267% YoY).","Growth driven by launch of Elite Laboratories label product line."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028684","json":"https://secwatch.observer/filing/0001493152-23-028684.json","markdown":"https://secwatch.observer/filing/0001493152-23-028684.md","text":"https://secwatch.observer/filing/0001493152-23-028684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/0001493152-23-028684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:55:04.283684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1be5a3c0acd98c135e7e2b8be2ec2e8db1d2fa31","claim":"ELITE PHARMACEUTICALS INC /NV/ reported first quarter of fiscal year 2024 ended June 30, 2023 results: revenue $9.0 million, net income $1.1 million.","evidence_excerpt":"Consolidated revenues for the three-month period ended June 30, 2023, were $9.0 million, an increase of $1.3 million or 16.9% as compared to the comparable period of the prior fiscal year. Operating profits were $1.6 million, an increase of $0.6 million or 60% from the comparable period of the prior year. Net income attributable to common shareholders was $1.1 million, an increase of $0.8 million or 267% from the comparable period of the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223028684/0001493152-23-028684-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal year 2024 ended June 30, 2023"},{"label":"Revenue","value":"$9.0 million"},{"label":"Net income","value":"$1.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}